Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNYSE:QGENNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$21.64+0.9%$23.73$15.19▼$26.58$2.62B0.661.12 million shs687,432 shsQGENQIAGEN$48.34-0.6%$44.83$37.63▼$49.30$10.75B0.681.20 million shs770,537 shsROIVRoivant Sciences$10.85-1.1%$11.14$8.73▼$13.06$7.47B1.155.72 million shs3.31 million shsRVMDRevolution Medicines$37.00-0.5%$39.54$29.17▼$62.40$7.05B1.061.68 million shs1.11 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%-0.64%-14.43%-6.20%+41.35%QGENQIAGEN0.00%+1.21%+5.68%+26.41%+22.53%ROIVRoivant Sciences0.00%-4.78%-3.26%+14.64%+3.48%RVMDRevolution Medicines0.00%+0.24%-8.37%+18.14%+0.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.9181 of 5 stars3.61.00.03.93.23.33.8QGENQIAGEN4.0412 of 5 stars1.25.01.74.52.71.71.3ROIVRoivant Sciences1.5415 of 5 stars3.51.00.00.00.62.50.0RVMDRevolution Medicines4.5764 of 5 stars4.52.00.04.73.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.25Buy$32.8351.73% UpsideQGENQIAGEN 2.30Hold$49.402.19% UpsideROIVRoivant Sciences 3.00Buy$17.5061.36% UpsideRVMDRevolution Medicines 3.00Buy$67.5882.66% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, QGEN, RVMD, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025QGENQIAGENBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $53.006/25/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/24/2025QGENQIAGENBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$55.006/24/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.00 ➝ $73.006/24/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.006/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$534.65M4.94$2.47 per share8.77$6.10 per share3.55QGENQIAGEN$1.98B5.43$3.21 per share15.08$16.05 per share3.01ROIVRoivant Sciences$29.05M253.79N/AN/A$7.45 per share1.46RVMDRevolution Medicines$11.58M595.16N/AN/A$13.47 per share2.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.5713.7810.160.8736.91%42.45%36.59%8/6/2025 (Estimated)QGENQIAGEN$83.59M$0.40121.2019.652.464.68%14.61%8.80%7/30/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)Latest CPRX, QGEN, RVMD, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025QGENQIAGEN$0.60N/AN/AN/A$523.97 millionN/A5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/7/2025Q1 2025QGENQIAGEN$0.50$0.55+$0.05$0.41$465.66 million$483.46 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AQGENQIAGEN$0.250.52%N/A62.50%N/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ALatest CPRX, QGEN, RVMD, and ROIV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/1/2025QGENQIAGEN$0.250.52%7/2/20257/3/20257/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.145.96QGENQIAGEN0.403.372.83ROIVRoivant SciencesN/A33.4733.47RVMDRevolution MedicinesN/A13.4613.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%QGENQIAGEN70.00%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%QGENQIAGEN9.00%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.98 million109.29 millionOptionableQGENQIAGEN5,765222.29 million202.29 millionOptionableROIVRoivant Sciences860679.81 million626.10 millionOptionableRVMDRevolution Medicines250186.27 million170.99 millionOptionableCPRX, QGEN, RVMD, and ROIV HeadlinesRecent News About These CompaniesLeerink Partnrs Issues Positive Estimate for RVMD EarningsJuly 4 at 2:35 AM | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Position Boosted by WCM Investment Management LLCJuly 3 at 5:38 AM | marketbeat.comRevolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS (ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - NasdaqJuly 2 at 11:21 AM | nasdaq.comLeerink Partnrs Issues Optimistic Estimate for RVMD EarningsJuly 2 at 7:41 AM | marketbeat.comRevolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant TumorsJune 30, 2025 | globenewswire.comLunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)June 29, 2025 | marketbeat.comBrokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Target Price at $67.58June 29, 2025 | americanbankingnews.comQ3 EPS Estimate for Revolution Medicines Raised by AnalystJune 27, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from GuggenheimJune 26, 2025 | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by AnalystsJune 26, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Needham & Company LLCJune 26, 2025 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Given Outperform Rating at WedbushJune 26, 2025 | americanbankingnews.comRevolution Medicines' (RVMD) Buy Rating Reiterated at GuggenheimJune 25, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | NasdaqJune 24, 2025 | nasdaq.comNeedham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What HappenedJune 24, 2025 | marketbeat.comRoyalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drugJune 24, 2025 | reuters.comRevolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted CancersJune 24, 2025 | globenewswire.comRevolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...June 23, 2025 | finanznachrichten.deRevolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 MutationsJune 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPRX, QGEN, RVMD, and ROIV Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$21.64 +0.19 (+0.89%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$21.35 -0.29 (-1.34%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.QIAGEN NYSE:QGEN$48.34 -0.30 (-0.62%) As of 07/3/2025 03:30 PM EasternQIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$10.84 -0.13 (-1.14%) Closing price 07/3/2025 03:45 PM EasternExtended Trading$10.94 +0.09 (+0.83%) As of 07/3/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$37.00 -0.19 (-0.51%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$37.39 +0.39 (+1.05%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
